000284613 001__ 284613
000284613 005__ 20240229155053.0
000284613 0247_ $$2doi$$a10.1097/HS9.0000000000000959
000284613 0247_ $$2pmid$$apmid:37810550
000284613 0247_ $$2pmc$$apmc:PMC10553128
000284613 0247_ $$2altmetric$$aaltmetric:155259036
000284613 037__ $$aDKFZ-2023-02032
000284613 041__ $$aEnglish
000284613 082__ $$a610
000284613 1001_ $$0P:(DE-He78)5b127bc6b2eee08c7aa37c90e72ea340$$aLux, Susanne$$b0$$eFirst author$$udkfz
000284613 245__ $$aEVI1-mediated Programming of Normal and Malignant Hematopoiesis.
000284613 260__ $$a[Philadelphia, Pennsylvania]$$bWolters Kluwer Health$$c2023
000284613 3367_ $$2DRIVER$$aarticle
000284613 3367_ $$2DataCite$$aOutput Types/Journal article
000284613 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1696923015_20952$$xReview Article
000284613 3367_ $$2BibTeX$$aARTICLE
000284613 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284613 3367_ $$00$$2EndNote$$aJournal Article
000284613 500__ $$aDKFZ-ZMBH Alliance / #EA:A012#LA:A012#
000284613 520__ $$aEcotropic viral integration site 1 (EVI1), encoded at the MECOM locus, is an oncogenic zinc finger transcription factor with diverse roles in normal and malignant cells, most extensively studied in the context of hematopoiesis. EVI1 interacts with other transcription factors in a context-dependent manner and regulates transcription and chromatin remodeling, thereby influencing the proliferation, differentiation, and survival of cells. Interestingly, it can act both as a transcriptional activator as well as a transcriptional repressor. EVI1 is expressed, and fulfills important functions, during the development of different tissues, including the nervous system and hematopoiesis, demonstrating a rigid spatial and temporal expression pattern. However, EVI1 is regularly overexpressed in a variety of cancer entities, including epithelial cancers such as ovarian and pancreatic cancer, as well as in hematologic malignancies like myeloid leukemias. Importantly, EVI1 overexpression is generally associated with a very poor clinical outcome and therapy-resistance. Thus, EVI1 is an interesting candidate to study to improve the prognosis and treatment of high-risk patients with 'EVI1high' hematopoietic malignancies.
000284613 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000284613 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000284613 7001_ $$0P:(DE-He78)7b613cadb8c16ce178713e15b85d982c$$aMilsom, Michael$$b1$$eLast author$$udkfz
000284613 773__ $$0PERI:(DE-600)2922183-3$$a10.1097/HS9.0000000000000959$$gVol. 7, no. 10, p. e959 -$$n10$$pe959$$tHemaSphere$$v7$$x2572-9241$$y2023
000284613 909CO $$ooai:inrepo02.dkfz.de:284613$$pVDB
000284613 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)5b127bc6b2eee08c7aa37c90e72ea340$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000284613 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7b613cadb8c16ce178713e15b85d982c$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000284613 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000284613 9141_ $$y2023
000284613 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-06-14T08:57:17Z
000284613 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-06-14T08:57:17Z
000284613 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Double anonymous peer review$$d2023-06-14T08:57:17Z
000284613 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-09-04
000284613 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-09-04
000284613 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-09-04
000284613 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-09-04
000284613 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHEMASPHERE : 2022$$d2023-10-27
000284613 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-27
000284613 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-27
000284613 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-27
000284613 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-27
000284613 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-27
000284613 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-27
000284613 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bHEMASPHERE : 2022$$d2023-10-27
000284613 9202_ $$0I:(DE-He78)A012-20160331$$kA012$$lA012 Experimentelle Hämatologie$$x0
000284613 9200_ $$0I:(DE-He78)A012-20160331$$kA012$$lA012 Experimentelle Hämatologie$$x0
000284613 9201_ $$0I:(DE-He78)A012-20160331$$kA012$$lA012 Experimentelle Hämatologie$$x0
000284613 980__ $$ajournal
000284613 980__ $$aVDB
000284613 980__ $$aI:(DE-He78)A012-20160331
000284613 980__ $$aUNRESTRICTED